Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Abstract
AIMS/HYPOTHESIS: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear. One potentially contributing factor is hyperexpression of HLA class I antigens. This was first described approximately 30 years ago, but has never been fully characterised and was recently challenged as artefactual. Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes. The principal aims were to consider whether HLA class I hyperexpression is artefactual and, if not, to determine the factors driving it. METHODS: Pancreas samples from type 1 diabetes patients with residual insulin-containing islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain containing 5 (NLRC5) and islet hormones. RNA was extracted from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analysed using gene-expression arrays. RESULTS: Hyperexpression of HLA class I was observed in the insulin-containing islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels. The expression of β2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated. Both 'classical' HLA class I isoforms (i.e. HLA-ABC) as well as a 'non-classical' HLA molecule, HLA-F, were hyperexpressed in insulin-containing islets. This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5. However, it was strongly associated with increased STAT1 expression in all three cohorts. Islet hyperexpression of HLA class I molecules occurred in the insulin-containing islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter. CONCLUSIONS/INTERPRETATION: Islet cell HLA class I hyperexpression is not an artefact, but is a hallmark in the immunopathogenesis of type 1 diabetes. The response is closely associated with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction.
Overview
CoChat Summary
TL;DR
This study reports that islet-cell HLA class I hyperexpression is real, reproducible across three type 1 diabetes pancreas cohorts, and present at both protein and RNA levels. The hyperexpression is associated with elevated STAT1, not NLRC5, and is strongest in insulin-containing islets near diagnosis, then declines with disease duration.
Key findings
- HLA class I hyperexpression was observed in insulin-containing islets from all three cohorts and was not seen in controls; it was restricted mainly to insulin-containing islets, while insulin-deficient islets showed normal expression.
- In laser-captured islets, RNA levels were elevated for HLA-A (1.9 ± 0.14-fold), HLA-B (2.15 ± 0.16-fold), HLA-C (2.02 ± 0.09-fold), and β2-microglobulin (2.07-fold) in the DiViD cohort; nPOD showed similar but less marked trends.
- A non-classical HLA molecule, HLA-F, was also upregulated, by 1.71 ± 0.04-fold at the RNA level in DiViD and confirmed at the protein level.
- STAT1 correlated positively with HLA-ABC expression, with Spearman’s r = 0.5454, p < 0.0001; by contrast, NLRC5 did not correlate with HLA-ABC hyperexpression (p = 0.4504).
- HLA-ABC hyperexpression was seen in patients with disease duration up to 11 years and then declined; the proportion of insulin-containing islets hyperexpressing HLA-ABC decreased with duration (r = –0.883, p < 0.0001).
Methods
- Pancreas tissue from 26 type 1 diabetes patients with residual insulin-containing islets and 17 control individuals was analyzed across three cohorts: nPOD, DiViD, and a UK collection.
- FFPE and frozen sections were stained for HLA class I isoforms, STAT1, NLRC5, β2-microglobulin, and islet hormones; islets from nPOD and DiViD were also laser-capture microdissected for RNA extraction.
- Gene-expression arrays were used for RNA analysis, and statistical testing used t tests or Satterthwaite corrected two-sample tests, with p < 0.05 as the significance threshold.
Limitations
- The paper states that the disease process in living patients cannot be studied non-invasively, so conclusions rely on tissue recovered after death or by pancreas biopsy.
- The authors note that HLA-I hyperexpression had previously been studied in relatively few patients, and that earlier RNA studies were limited; this paper addresses that by using more cohorts and samples.
- Evident from the text: the RNA analyses were performed on pooled, laser-captured islets that did not distinguish hyperexpressing from normal islets, or insulin-containing from insulin-deficient islets at collection, which limits cell-level specificity of the transcript data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
0 Valid · 0 Not valid · 16 Not checked · 36 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, it was strongly associated with increased STAT1 expression in all three cohorts.”
- Also stated in: § Signal transducer and activator of transcription 1 (STAT1) expression correlates positively with HLA-ABC hyperexpression in type 1 diabetes · boosted
“This revealed a striking positive correlation between STAT1 and HLA-ABC expression (Fig. 6b, overall Spearman’s r = 0.5454, p < 0.0001).”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Abstract > Results
boostedstates an associationn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Signal transducer and activator of transcription 1 (STAT1) expression correlates positively with HLA-ABC hyperexpression in type 1 diabetes · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Islet hyperexpression of HLA-ABC was not confined solely to beta cells, but occurred in all islet endocrine cells (Fig. 1, ESM Fig. 1b).”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Results > Lobular hyperexpression of HLA-A, -B and -C (HLA-ABC) in type 1 diabetes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it was observed that a non-classical HLA, HLA-F, was also upregulated (by 1.71 ± 0.04-fold) when analysed across all probe sets (Fig. 4a).”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Results > HLA-F expression is also elevated in the ICIs of individuals with recent-onset type 1 diabetes
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Quantification yielded mean ± SEM increases of 1.9 ± 0.14-fold, 2.15 ± 0.16-fold, 2.02 ± 0.09-fold for HLA-A, -B and -C, respectively, and 2.07-fold for β2M.”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Results > Expression of RNA transcripts encoding HLA or β2M in laser-captured, microdissected islets
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consistent with this, the most pronounced rise was seen in islets harvested by laser-capture microdissection from the six DiViD patients (p = 0.0263; Fig. 6d, ESM Fig. 7), who were studied very close to disease onset.”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Results > Signal transducer and activator of transcription 1 (STAT1) expression correlates positively with HLA-ABC hyperexpression in type 1 diabetes
plainstates an associationn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 52 claims and to verify the 34 references still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 8
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603 · cited 1×
“Raw signal intensity values from all arrays were Robust Multichip Average (RMA) background corrected, quantile normalized, median polish summarized, and log2transformed [25-27].”
MethodAtkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931 · cited 3×
“Despite these limitations, a consensus model has emerged in which type 1 diabetes is envisaged to result from the selective destruction of beta-cells by immune cells infiltrating the islets of Langerhans [1-3, 8, 9].”
Self-citationMicroarray data normalization and transformation
Quackenbush, J. (2002) · Nature Genetics · doi:10.1038/ng1032 · Cited by 1,975 · cited 1×
“Raw signal intensity values from all arrays were Robust Multichip Average (RMA) background corrected, quantile normalized, median polish summarized, and log2transformed [25-27].”
Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A., & Soltész, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60568-7 · Cited by 1,854 · cited 2×
“Despite these limitations, a consensus model has emerged in which type 1 diabetes is envisaged to result from the selective destruction of beta cells by immune cells infiltrating the islets of Langerhans [1–3, 8, 9].”
A Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716 · cited 1×
“Raw signal-intensity values from all arrays were robust multichip average background corrected, quantile normalised, median polish summarised and log 2 transformed [25–27].”
Bottazzo, G. F., Dean, B. M., McNally, J. M., MacKay, E. H., Swift, P. G. F., & Gamble, D. R. (1985) · New England Journal of Medicine · doi:10.1056/nejm198508083130604 · Cited by 932 · cited 1×
“This could be achieved in several ways, including via the up-regulated expression of the major histocompatibility complex (HLA class I molecules) [15-17].”
Analysis of islet inflammation in human type 1 diabetes
Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K., & Morgan, N. G. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2008.03860.x · Cited by 712 · cited 5×
“1), while insulin-deficient islets (IDIs) displayed normal expression.”
InfluentialSelf-citationCoppieters, K. T., Dotta, F., Amirian, N., Campbell, P. D., Kay, T. W. H., Atkinson, M. A., Roep, B. O., & von Herrath, M. G. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111187 · Cited by 672 · cited 2×
“It is also likely, however, that beta cells are complicit in these events by aberrantly processing and presenting cellular antigens, thereby becoming visible to autoreactive CD8 Tcells [14].”
Self-citationFoulis, A. K., Liddle, C. N., Farquharson, M. A., Richmond, J. A., & Weir, R. S. (1986) · Diabetologia · doi:10.1007/bf00452061 · Cited by 469 · cited 2×
“Hence, deductions regarding pathogenic processes are made from analyses of tissue recovered either after death or by pancreas biopsy in living individuals [4–7].”
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Meissner, T. B., Li, A., Biswas, A., Lee, K.-H., Liu, Y.-J., Bayir, E., Iliopoulos, D., van den Elsen, P. J., & Kobayashi, K. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008684107 · Cited by 447 · cited 1×
“NLR familyCARDdomain containing 5 (NLRC5) expression does not correlate with HLA-ABC hyperexpression In order to understand the factors that might drive islet HLA-I hyperexpression in type 1 diabetes, we studied NLRC5, a known transcriptional regulator of HLA-ABC and β2M [31].”
Cited by
Items 201–300 of 300
Brown, M. E., Barra, J. M., Pina, M., Proia, J., Brusko, T. M., & Russ, H. A. (2025) · Science Advances · doi:10.1126/sciadv.adx9755 · Cited by 8
Is the NOD mouse a good model for type 1 diabetes?
Wong, F. S., Pearson, J. A., & Li, W. (2025) · Diabetologia · doi:10.1007/s00125-025-06579-0 · Cited by 8
“HLA class I upregulation is a sign of inflammation in stressed cells, one cause of which may be production of IFNs, often induced by viral infection [32] (but also by endogenous dsRNA, bacteria and mycoplasma).”
Medina-Serpas, M. A., Brusko, M., Golden, G. J., Campbell‐Thompson, M., Rogers, T., Reardon, S., Posgai, A. L., Bacher, R. L., Prak, E. T. L., Liu, C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117144 · Cited by 10
“To determine the relative contributions of follicular B cells, follicular T cells (Tfh cells), or T cells in the adjacent TCZ toward enhanced LTB expression observed in T1D follicles, we performed imaging-based, subcellular-resolution ST on FFPE pLN sections from two age-matched (no. 6374, ND, 14 years of age, and no.…”
InfluentialSelf-citationBeyond bystanders: How β cell stress shapes the autoimmune response in T1D
Engin, F., & Eizirik, D. L. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aed3762 · Cited by 9
JAK inhibitors: a new choice for diabetes mellitus?
Zhou, M., Shen, Q., & Li, B. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01582-2 · Cited by 10
What Have Slow Progressors Taught Us About T1D—Mind the Gap!
Gillespie, K. M., & Long, A. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1219-1 · Cited by 9
Khilji, M. S., Faridi, P., Pinheiro-Machado, E., Hoefner, C., Dahlby, T., Aranha, R., Buus, S., Nielsen, M., Klusek, J. E., Mandrup-Poulsen, T. R., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10040814 · Cited by 7
Lindbladh, I., Svärd, A. A., & Lernmark, Å. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00041-5 · Cited by 9
Svensson, S., Trobos, M., Omar, O., & Thomsen, P. (2017) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36088 · Cited by 8
Poma, A. M., Hammerstad, S. S., Genoni, A. P., Basolo, A., Dahl‐Jørgensen, K., & Toniolo, A. (2021) · Microorganisms · doi:10.3390/microorganisms9040876 · Cited by 7
“In pancreatic islets, the demonstrated upregulation of HLA class I and STAT1 genes likely reflects an enduring antiviral response [14].”
BackgroundSelf-citationβ Cell replacement: improving on the design.
Castro-Gutiérrez, R., Michels, A. W., & Russ, H. A. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000418 · Cited by 6
Transcriptomics of autoimmune diseases identifies FGFR1 as a target for pancreatic β-cell protection
Yi, X., Zimath, P. L., Martín-Vázquez, E., Oliveira, J. G., Jawurek, S., Title, A. C., Yesildag, B., Mourad, N. I., Buemi, A., Pattou, F. N., et al. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103469 · Cited by 7
Perego, C., Cairano, E. S. D., Galli, A., Moretti, S., Bazzigaluppi, E., Centonze, V. F., Gastaldelli, A., Assi, E., Fiorina, P., Federici, M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106130 · Cited by 6
Toledo, M. P., Xie, G., & Wang, Y. J. (2024) · Endocrinology · doi:10.1210/endocr/bqae094 · Cited by 8
Välikangas, T., Lietzén, N., Jaakkola, M. K., Krogvold, L., Eike, M. C., Kallionpää, H., Tuomela, S., Mathews, C. E., Gerling, I., Oikarinen, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.861985 · Cited by 6
Self-citationTemporal regulation of interferon signalling in human EndoC-βH1 cells
Dhayal, S., Leslie, K. A., Baity, M., Akhbari, P., Richardson, S. J., Russell, M. A., & Morgan, N. G. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-21-0224 · Cited by 5
Self-citationTekin, H., Josefsen, K. E., Krogvold, L., Dahl‐Jørgensen, K., Gerling, I., Pociot, F., & Buschard, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-22890-x · Cited by 7
Self-citationCantley, J., Eizirik, D. L., Latres, E., Dayan, C. M., & _, _. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0082 · Cited by 10
Identifying the ‘Achilles heel’ of type 1 diabetes
Battaglia, M., Buckner, J. H., Levings, M. K., Richardson, S. J., Wong, F. S., & Tree, T. I. M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13570 · Cited by 6
Self-citationSemeraro, M. L., Glenn, L. M., & Morris, M. A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00246 · Cited by 6
Derr, A. G., Arowosegbe, A., Satish, B., Redick, S. D., Qaisar, N., Guo, Z., Vanderleeden, E., Trombly, M. I., Baer, C. E., Harlan, D. M., et al. (2022) · Diabetes · doi:10.2337/db22-0521 · Cited by 5
Christoffersson, G. (2021) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2021.100057 · Cited by 5
Hansen, M., Pokharel, P., Piganelli, J. D., & Sussel, L. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041591 · Cited by 8
Samassa, F., Holtzmann, C., & Mallone, R. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041604 · Cited by 5
IFN-α Induces Heterogenous ROS Production in Human β-CellsPreprint
Wagner, L. E., Melnyk, O., Turner, A., Duffett, B. E., Muralidharan, C., Irizarry, M. M. M., Arvin, M. C., Orr, K. S., Manduchi, E., Kaestner, K. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.19.639120 · Cited by 5
Veronese-Paniagua, D., & Millman, J. R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1734431 · Cited by 6
Batdorf, H. M., Lawes, L. D. L., Richardson, J. T., Burk, D. H., Dupuy, S. D., Karlstad, M. D., Noland, R. C., Burke, S. J., & Collier, J. J. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00033.2023 · Cited by 4
Repositioning the Early Pathology of Type 1 Diabetes to the Extraislet Vasculature
Costanzo, A. E., Clarke, D., Holt, M., Sharma, S. M., Nagy, K., Tan, X., Kain, L., Abe, B. T., Luce, S., Boîtard, C., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300769 · Cited by 6
“For CD8 killing it has been consistently shown that b cells express MHC class I molecules, especially after cytokine exposure (11); however, their ability to synthesize and display MHC class II is not a closed issue (12).”
BackgroundIFN-α Neutralizing Antibodies Distinguish LADA From Early-onset Type 1 Diabetes
Amendolara, R., D’Onofrio, L., Sessa, R. L., Giulio, S. D., Mignogna, C., Coraggio, L., Schirano, R., Zampetti, S., Malandrucco, I., Pozzilli, P., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf001 · Cited by 3
Hogendorf, A., Abel, M., Wyka, K., Bodalski, J., & Mlynarski, W. M. (2020) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2020.95617 · Cited by 4
“Recently, the well-established dogma about the origins of insulitis has changed as the solid evidence from histopathological studies such as DiViD or nPOD (7) confirmed that islet cell upregulation of HLA-I expression is a genuine pathological feature in type 1 diabetes in humans [8].”
BackgroundGiuliani, C., Verrocchio, S., Verginelli, F., Bucci, I., Grassadonia, A., & Napolitano, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.749609 · Cited by 4
Misra, P. S., & Nostro, M. C. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100321 · Cited by 5
Arresting type 1 diabetes: are we there yet? Obstacles and opportunities
Mathieu, C., & Martens, P.-J. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.16 · Cited by 5
Carré, A., Zhou, Z.-C., Perez-Hernandez, J., Samassa, F., Lekka, C., Manganaro, A., Oshima, M., Liao, H., Parker, R., Nicastri, A., et al. (2023) · bioRxiv · doi:10.1101/2023.09.15.557918 · Cited by 1
Self-citationKusmartseva, I., Posgai, A. L., Yang, M., Oram, R. A., Atkinson, M., Pugliese, A., & Evans‐Molina, C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041588 · Cited by 10
Self-citationHLA Class I and II genes: A key factor for type one diabetes susceptibility
Telang, G., Mishra, S., Sureshbabu, A., Chiloo, S., Joshi, S., & Thyagarajan, S. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102183 · Cited by 4
Oshima, M., Halliez, C., Kobaisi, F., Modé, N., Fouque, A., Brandao, B., Mayeur, O., Balboa, D., Mallone, R., & Scharfmann, R. (2025) · Diabetes · doi:10.2337/db25-0473 · Cited by 4
Dikranian, C., Hadara, O., & Lysy, P. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758848 · Cited by 3
Epidemiology and Pathogenesis of Type 1 Diabetes
Stene, L. C., & Lernmark, Å. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_2 · Cited by 4
Amarajeewa, A. W. P., Ozcan, A., Mukhtiar, A., Ren, X., Wang, Q., Özbek, P., Garstka, M. A., & Serçinoğlu, O. (2024) · European Journal of Immunology · doi:10.1002/eji.202350683 · Cited by 4
“Moreover, inflammatory conditions present in T1D augment HLA I surface levels in pancreatic beta cells [42].”
BackgroundWhat Is a Honeymoon in Type 1, Can It Go into Remission?
Viswanathan, A., Wood, J., & Hatipoğlu, B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.08.001 · Cited by 3
Sundstrom, J., Vanderleeden, E., Barton, N., Redick, S. D., Dawes, P., Murray, L. F., Olson, M. N., Tran, K. V., Chigas, S. M., Orszulak, A. R., et al. (2024) · Preprints.org · doi:10.20944/preprints202407.1267.v1 · Cited by 3
Swensen, A., Piehowski, P., Chen, J., Chan, X. Y., Kelly, S. S., Petyuk, V., Moore, R. J., Nasif, L. H., Butterworth, E. A., Atkinson, M. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.13.612933 · Cited by 3
Self-citationBeta cell–targeted PD-1 agonist inhibits cell-mediated autoimmunity in pancreas tissue slices
Becker, M. W., Brown, M. E., Wiseman, K., Chiodetti, A. L., Huber, M. K., Cuaycal, A. E., Sintara, P., Ferreira, S. M., Smurlick, D., Barra, J. M., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec9029 · Cited by 2
“T1D is characterized by HLA class I hyperexpression within islets ( 43 , 44 ).”
Self-citationType I Interferons as Contextual Regulators of B-Cell Tolerance in Type 1 Diabetes
Tedla, M. G., & Felton, J. L. (2026) · Biomolecules · doi:10.3390/biom16040563 · Cited by 2
“…at-risk children demonstrate that a peripheral IFN transcriptional signature precedes seroconversion and clinical onset [63], and pancreatic islets from individuals with recent onset T1D display marked HLA class I hyperexpression and induction of ISGs, consistent with local IFN exposure [67,68].”
Wagner, L. E., Melnyk, O., Muncy, A. N., Turner, A., Duffett, B. E., Muralidharan, C., Irizarry, M. M. M., Arvin, M. C., Orr, K. S., Wu, W., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx7770 · Cited by 7
Halliez, C., Ibrahim, H., Otonkoski, T., & Mallone, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1076683 · Cited by 3
Eizirik, D. L., Zimath, P. L., Yi, X., Roca-Rivada, A., & Richardson, S. J. (2024) · Diabetologia · doi:10.1007/s00125-024-06269-3 · Cited by 2
“Of particular relevance, the hyperexpression of HLA class I molecules on beta cells, a widely accepted histological feature of islets in type 1 diabetes [7, 8], was induced only by IFN-α and IFN-γ [2].”
Self-citationPathogenesis of Type 1 Diabetes
Pugliese, A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_7 · Cited by 3
Self-citationIdentification of Peripheral Blood Endotypes Associated With Age in Pediatric Type 1 Diabetes
Gómez-Muñoz, L., Perna-Barrull, D., Ventura, P. S., Valls, A., Castiello, F., Vives-Pi, M., & Murillo-Vallés, M. (2025) · Pediatric Diabetes · doi:10.1155/pedi/5512196
“Notably, evidence suggests that insulin-containing islets may actively defend themselves against the autoimmune reaction by upregulating nonclassical class I HLA molecules like HLA-F, as well as inhibitory molecules like PD-L1 [11, 12].”
Friend or foe: New cytokine players in beta cell failure in type 1 diabetes mellitus
Gurgul-Convey, E., & Naujok, O. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120113 · Cited by 2
Epigenetic Modifications and Their Role in Type 1 Diabetes Development: A Review
de Azevedo, J. C. V., Fernandes, F. L., Rodrigues, T. D., de Medeiros, I. A. C. M., Andrade, V. S., de Araújo, J. M. G., Bezerra, F. L., Bezerra, C. M., Fernandes, T. A. A. D. M., & Fernandes, J. V. (2026) · Current Diabetes Reviews · doi:10.2174/0115733998399336251122042738 · Cited by 1
Amdare, N., Ali, R., Manganaro, A., Baker, J. C., Antal, Z., Smith, C., Santamaria, P., Kent, S. C., & Dilorenzo, T. (2026) · Journal of Immunology · doi:10.1093/jimmun/vkaf381 · Cited by 1
Pugliese, A. (2026) · Diabetes · doi:10.2337/dbi25-0052 · Cited by 2
Self-citationImmunotherapy for Diabetogenic Pancreatitis and Pancreatic Cancer: An Update
Mungamuri, S. K., Pasupulati, A. K., & Mavuduru, V. A. (2019) · Springer eBooks · doi:10.1007/978-981-32-9393-9_13 · Cited by 2
Thompson, P. J., & Bhushan, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822514-1.00008-0 · Cited by 1
Sharma, R., Amdare, N. P., Ghosh, A., Schloss, J. M., Sidney, J., Garforth, S., Lopez, Y., Celikgil, A., Sette, A., Almo, S. C., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107702 · Cited by 2
“This is a critical area of study, given the mounting evidence that cytotoxic CD8 + T cells are important effectors in beta cell elimination (10 – 15), coupled with the observation that T1D is associated with hyper-expression of class I MHC on beta cells (16).”
Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats
Arowosegbe, A., Guo, Z., Vanderleeden, E., Derr, A. G., & Wang, J. P. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103358 · Cited by 2
Pathogenesis of Type 1 Diabetes
Pugliese, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_7-1 · Cited by 1
Self-citationHuman islet T cells are highly reactive to preproinsulin in type 1 diabetes
Anderson, A. M., Landry, L. G., Alkanani, A. K., Pyle, L., Powers, A. C., Atkinson, M. A., Mathews, C. E., Roep, B. O., Michels, A. W., & Nakayama, M. (2022) · Yearbook of pediatric endocrinology · doi:10.1530/ey.19.10.13 · Cited by 1
Chemical Approaches for Beta-cell Biology
Vetere, A., Parekh, V. S., Modell, A. E., Shoba, V. M., Choudhary, A., & Wagner, B. K. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165498-00001 · Cited by 1
Sakaguchi, S., Tsutsumi, M., Nishi, K., & Naoki, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648296 · Cited by 1
“In the NOD condition beta-2 microglobulin ( B2m ), a type I diabetic marker [28], showed higher expression than other conditions, and three db/db conditions showed higher expression of type II diabetic markers: aldehyde dehydrogenase family 1, subfamily A3 ( Aldh1a3 ) [29], vitamin D binding…”
Beta cell reactivity defines disease-relevant pancreatic CD8 T cells in type 1 diabetesPreprint
Anderson, A. M., Landry, L. G., Barra, J. M., Wells, K. L., Shilleh, A. H., Castro-Gutiérrez, R., Ladd, A. M., DeNicola, M., Babon, J. A. B., Mallone, R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.08.729940 · Cited by 1
“Histological analyses further reveal elevated HLA-I expression on beta cells in the pancreata of T1D organ donors, especially involving HLA-B molecules ( 13, 18, 19 ).”
HLA-I-Überexpression auf Inselzellen maßgeblich für Genese des Typ-1-Diabetes
Schloot, N. C. (2017) · Info Diabetologie · doi:10.1007/s15034-017-1031-4
Jecht, M. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0371-6
Leslie, K. A. (2019) · Figshare
The role of immune regulatory cells in sight-threatening non-infectious uveitis
Zhang, X. (2019) · UCL Discovery (University College London)
Thivolet, C. H. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.07.004
Gerling, I. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738336752.793578019
Self-citationFallimento β-cellulare nel diabete mellito di tipo 1 e di tipo 2: esistono meccanismi comuni?
Marrano, N., Biondi, G., Giorgino, F., & Natalicchio, A. (2022) · il Diabete · doi:10.30682/ildia2202g
Modeling Type 1 Diabetes progression from single-cell transcriptomic measurements in human isletsPreprint
Patil, A. R., Schug, J., Liu, C., Lahori, D., Descamps, H. C., Naji, A., Kaestner, K. H., Faryabi, R. B., & Vahedi, G. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.19.549708
Buschard, K., Josefsen, K. E., Krogvold, L., Gerling, I., Dahl‐Jørgensen, K., & Pociot, F. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3792
“Frozen sections of the pancreatic tissue were subjected to laser capture dissection 16 and islets from two to five sections were pooled, and RNA was extracted, using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Grand Is-land).”
MethodSelf-citationHuman beta cells become dysfunctional prior to type 1 diabetes diagnosisPreprint
Teitelman, G. (2024) · Research Square · doi:10.21203/rs.3.rs-5285252/v1
TLR-5 influences T cell activity: implications for development of Type 1 DiabetesPreprint
Buschard, K., Krogvold, L., Gerling, I., Dahl‐Jørgensen, K., Pociot, F., & Hansen, C. H. F. (2025) · Research Square · doi:10.21203/rs.3.rs-5782494/v1
Self-citationJönsson, J., & Lernmark, Å. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00176-9 · Cited by 1
Dai, Y. D., Li, S., Margosiak, A., & Hu, W. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlaf033
“19,20 Notably, HLA-E, the human homolog of Qa-1, is upregulated in the islets of patients with type 1 diabetes (T1D), 21,22 and its expression in pancreatic islets is likely influenced by local antiviral responses and interferon (IFN) signaling.”
Becker, M. W., Brown, M. E., Wiseman, K., Chiodetti, A. L., Huber, M. K., Cuaycal, A. E., Sintara, P., Ferreira, S. M., Smurlick, D., Barra, J. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.21.683528
“T1D is characterized by HLA class I hyperexpression within islets ( 43, 44 ).”
Self-citationTeitelman, G. (2025) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554251387770
Long non-coding RNAs as a novel source of beta cell autoantigens in type 1 diabetesPreprint
Mentxaka, J., Callebaut, A., García‐Etxebarria, K., Bergara-Muguruza, L., Pascual-González, I., Jones, A. R., Li, K., Márquez, H. R., Castellanos–Rubio, A., James, E. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.01.691527
“In parallel, HLA expression is upregulated in response to inflammatory stimuli in pancreatic beta cells[52–54], expanding the epitope landscape and arguably promoting the presentation of epitopes and neoepitopes, such as lncRNA derived peptides, that likely circumvent thymic tolerance…”
Veronese-Paniagua, D., Banks, C. E., Bradley, K., Mukherjee, N., Gale, S. E., Hinshaw, K. E., Meacham, A. M., Iwaloye, O. F., Tse, H. M., Mathews, C. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.30.697107
Self-citationYe, Y., QIU, Y., Aguilan, J. T., Sun, Y., Kulkarni, R., Jankauskas, S. S., Santulli, G., Sidoli, S., Kurland, I. J., & Tomer, Y. (2026) · Diabetes · doi:10.2337/db25-0191
Les cellules MAIT dans le diabète de type 1 chez l'homme
Nel, I. (2019) · theses.fr (ABES) · doi:10.70675/8eaa5bd8z1217z4729z8c2ezb385e0dbc1a9
Carré, A. (2022) · theses.fr (ABES) · doi:10.70675/28c85b2dz490az44c1zbbc4z061ea62b1e33
Degroote, L., Chrzanowski, J., Lemaître, P., Wouters, A., Bourgeois, S., Mulders, A. V., Pierreux, J., Coenen, S., Willems, L., Leuckx, G., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06750-1 · Cited by 1
“…hand, stressed beta cells re-express silenced ‘disallowed’ genes [57], altering metabolism and impairing insulin secretion, and increase their immune visibility through HLA class I and II hyperexpression [58, 59] and neo-epitope formation driven by stress-related enzymatic modifications [17, 60].”
Unlocking beta cell health: The clinical potential of extracellular vesicles in type 1 diabetes
Jayabalan, N., Carrión, F., Joshi, K., Huynh, T., & Salomón, C. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70700
“The endoplasmic reticulum (ER) stress in the β -cells as well as the expression of chemoattractants up-regulate the expression of HLA Class I 37 with the presentation of neoantigens 38,39 which attracts the T-cells and the binding of T-cells to these neoantigens on the β -cells triggers apoptosis.”
Parikh, S., Strobl, D. C., Jiménez, S., Beckmann, J., Arnoldt, L., Roellin, E., Vandenbempt, V., Sterr, M., Aije, M., Vu, H. T. H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733853 · Cited by 1
Islet-Targeted ZnT8 Antibodies Protect Pancreatic β-Cells From Inflammatory Stress
Guo, Z., Kasinathan, D., Yun, S., Golson, M. L., & Fu, D. (2026) · Diabetes · doi:10.2337/db26-0183
Erdem, N., Zook, H. N., Quijano, J. C., Hansen, N. P., Palade, J., Oh, E., Mares, J., Donohue, C., Ortiz, J. A., Jou, K., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1788321
Qu, B., Zeng, B., Yuan, Y., He, X., Ren, L., Zhu, H., & Guan, X. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02769-3
“During T1D development, β-cells upregulate HLA class I in response to inflammatory cytokines, particularly IFN-γ, which sensitizes them to recognition and killing by autore - active CD8 + T cells [ 19 ].”
Cuaycal, A. E., Butterworth, E. A., Stimpson, S. E., Chen, J., Lenchik, N. I., Baratta, L. A., Phelps, E. A., Grieshaber, S. S., Atkinson, M. A., Qian, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.29.741469
Self-citationShivamadhu, M. C., Zhang, X., Yechoor, V. K., Prentice, K. J., Razani, B., Wheeler, M. B., & Khan, M. S. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743319
Disentangling batch effects and biological signals across conditions in single-cell transcriptome
Sakaguchi, S., Tsutsumi, M., Nishi, K., & Naoki, H. (2026) · Patterns · doi:10.1016/j.patter.2026.101638 · Cited by 1
“For comparison, we examined the expression of B2m and C-X-C motif chemokine ligand 10 ( Cxcl10 ), which are true-positive genes whose upregulation has been experimentally validated 31,37 (Figure 6C, bottom two panels).”
Veronese-Paniagua, D., Banks, C. E., Bradley, K., Mukherjee, N., Gale, S. E., Hinshaw, K. E., Meacham, A. M., Iwaloye, O. F., Tse, H. M., Mathews, C. E., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117560
Self-citationWang, L., & Wei, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.25.753922
New insights into β‐cell vulnerability in type 1 diabetes—Lessons from nature
Murrall, K., Luckett, T., Lekka, C., Hunter, S. B., Agnello, S., Ferris, P., Haxton, E., Flaxman, C. S., Kannan, A., Dun, X., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70509
Self-citationSingle cell expression map of pancreatic islets using data from HPAP, IIDP and Prodo v3.5
Vu, H. T. H., Sun, H., Sharp, S., Kudtarkar, P., BRUSMAN, L., Jurgens, J., The PanKbase Consortium, Flannick, J. A., BURTT, N., Chen, S., et al. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.15588155 · Cited by 2
Single cell expression map of pancreatic islets using data from HPAP, IIDP and Prodo v1.0
Vu, H. T. H., Sun, H., Sharp, S., Kudtarkar, P., BRUSMAN, L., Jurgens, J., The PanKbase Consortium, Flannick, J. A., BURTT, N., Chen, S., et al. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.15588239
Metadata
- Authors
- Richardson, S. J., Rodriguez-Calvo, T., Gerling, I. C., Mathews, C. E., Kaddis, J. S., Russell, M. A., Zeissler, M., Leete, P., Krogvold, L., Dahl-Jørgensen, K., von Herrath, M., Pugliese, A., Atkinson, M. A., & Morgan, N. G.
- Affiliations
- University of Exeter (GB)
- University of Tennessee Health Science Center (US)
- University of Florida Health (US)
- City Of Hope National Medical Center (US)
- Oslo University Hospital (NO)
- University of Miami (US)
- Corresponding author
- Richardson, Sarah J.
- Morgan, Noel G.
- ORCID
- Venue
- Diabetologia
- Published
- 2016-08-09
- Volume
- 59
- Issue
- 11
- Pages
- 2448-2458
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC5042874
- OpenAlex
- W2513957711
- Cited by
- 298
- References
- 43
- Citations by year
- 2026: 26 · 2025: 39 · 2024: 30 · 2023: 23 · 2022: 36 · 2021: 37 · 2020: 28 · 2019: 33 · 2018: 25 · 2017: 19 · 2016: 2
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Funders
- Seventh Framework Programme (261441)
- Diabetes Research & Wellness Foundation
- National Institutes of Health (UC4 DK104155)
- JDRF (JDRF 25-2012-516)
- South-Eastern Norway Regional Health Authority
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- type 1 diabetes, pancreatic beta cells, islets, STAT1, NLRC5, HLA-F, beta2-microglobulin, islet autoimmunity, immunopathogenesis, recent-onset type 1 diabetes, disease duration, islet gene expression, HLA-ABC
- MeSH terms
- Diabetes Mellitus, Type 1, Female, Fluorescent Antibody Technique, Humans, Immunohistochemistry, Insulin, Islets of Langerhans, Male, Pancreas, Histocompatibility Antigens Class I, STAT1 Transcription Factor, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.